Gilead Sciences, Inc. (LON:0QYQ)

Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of GBP 139.22 billion. The enterprise value is 149.59 billion.

Market Cap	139.22B
Enterprise Value	149.59B

Important Dates

The last earnings date was Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Dec 15, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	88.90%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 22.02 and the forward PE ratio is 17.32.

PE Ratio	22.02
Forward PE	17.32
PS Ratio	6.36
PB Ratio	8.28
P/TBV Ratio	n/a
P/FCF Ratio	19.82
P/OCF Ratio	18.70
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.84, with an EV/FCF ratio of 21.29.

EV / Earnings	23.66
EV / Sales	6.85
EV / EBITDA	13.84
EV / EBIT	17.08
EV / FCF	21.29

Financial Position

The company has a current ratio of 1.68, with a Debt / Equity ratio of 1.09.

Current Ratio	1.68
Quick Ratio	1.31
Debt / Equity	1.09
Debt / EBITDA	1.69
Debt / FCF	2.60
Interest Coverage	11.54

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 27.55%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.52%
Return on Invested Capital (ROIC)	27.55%
Return on Capital Employed (ROCE)	25.03%
Weighted Average Cost of Capital (WACC)	6.06%
Revenue Per Employee	1.24M
Profits Per Employee	359,257
Employee Count	17,600
Asset Turnover	0.50
Inventory Turnover	2.05

Taxes

In the past 12 months, Gilead Sciences has paid 955.50 million in taxes.

Income Tax	955.50M
Effective Tax Rate	13.13%

Stock Price Statistics

The stock price has increased by +41.72% in the last 52 weeks. The beta is 0.39, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	+41.72%
50-Day Moving Average	133.39
200-Day Moving Average	119.55
Relative Strength Index (RSI)	63.75
Average Volume (20 Days)	28,438

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.21

Income Statement

In the last 12 months, Gilead Sciences had revenue of GBP 21.88 billion and earned 6.32 billion in profits. Earnings per share was 5.04.

Revenue	21.88B
Gross Profit	17.25B
Operating Income	8.78B
Pretax Income	7.28B
Net Income	6.32B
EBITDA	10.83B
EBIT	8.78B
Earnings Per Share (EPS)	5.04

Balance Sheet

The company has 7.88 billion in cash and 18.27 billion in debt, with a net cash position of -10.39 billion.

Cash & Cash Equivalents	7.88B
Total Debt	18.27B
Net Cash	-10.39B
Net Cash Per Share	n/a
Equity (Book Value)	16.81B
Book Value Per Share	13.54
Working Capital	6.00B

Cash Flow

In the last 12 months, operating cash flow was 7.44 billion and capital expenditures -418.31 million, giving a free cash flow of 7.03 billion.

Operating Cash Flow	7.44B
Capital Expenditures	-418.31M
Free Cash Flow	7.03B
FCF Per Share	n/a

Margins

Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.

Gross Margin	78.84%
Operating Margin	40.14%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	49.52%
EBIT Margin	40.14%
FCF Margin	32.12%

Dividends & Yields

This stock pays an annual dividend of 2.36, which amounts to a dividend yield of 1.56%.

Dividend Per Share	2.36
Dividend Yield	1.56%
Dividend Growth (YoY)	-1.78%
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.24%
Shareholder Yield	1.80%
Earnings Yield	4.54%
FCF Yield	5.05%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	8